FLT3‐targeted therapy has also been shown to improve long‐term outcome when administered as maintenance therapy of FLT3 mutated AML after allogeneic stem cell transplantation [27, 28], a disease state characterised by low tumour burden and anti‐leukemic immunological mechanisms. Here, FLT3 is linked to neoplasm.